Anna C Ferrari
ECOG-ACRIN Cancer Research Group · New York University Cancer Institute · NYU Langone Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anna C Ferrari as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:18 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01251861 · Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerNational Cancer Institute (NCI) · completed · Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7 · principal investigator
- Ph2NCT01194960 · TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)Oxford BioMedica · terminated · Hormone Refractory Prostate Cancer · principal investigator
- Ph2NCT00685633 · Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate CancerEastern Cooperative Oncology Group · withdrawn · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- GenitourinaryP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2008 to 2012 · $31,050 awarded in 2012Same name and institution; not confirmed by an ID
- KLF6 Gene and Clinical Correlates in Prostate CancerR01CA098135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2003 to 2005 · $338,423 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT01251861
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT01251861
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:18 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med · 20104,465 citationsRCR 103.9
- Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.Clin Cancer Res · 201959 citationsRCR 1.9
- Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.Clin Cancer Res · 202054 citationsRCR 1.9
- 45 citationsRCR 1.1
- 23 citationsRCR 0.7
- 13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: report of a phase II randomized study.J Clin Oncol · 200212 citationsRCR 0.2